Drugs / PG4
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06531538 | Jul 2024 → Feb 2026 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT06524414 | Jul 2024 → May 2027 expected | pneumococcal infection | Pfizer | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07660198 | Jun 2026 → Dec 2027 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07629440 | May 2026 → Jun 2029 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07573462 | May 2026 → Dec 2028 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660198 ↗ |
| Modality | Vaccine | “Multivalent Pneumococcal Vaccine” NCT07629440 ↗ |
| Route | Intramuscular | “All study vaccines will be given as a single shot into the left thigh muscle.” NCT06524414 ↗ |